Lao-Tzu S. Allan-Blitz, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gonorrhea | 15 | 2023 | 346 | 5.700 |
Why?
|
| Neisseria gonorrhoeae | 15 | 2023 | 239 | 5.470 |
Why?
|
| Ciprofloxacin | 12 | 2023 | 312 | 3.940 |
Why?
|
| DNA Gyrase | 8 | 2023 | 85 | 3.280 |
Why?
|
| Sexually Transmitted Diseases | 5 | 2023 | 662 | 2.560 |
Why?
|
| Drug Resistance, Bacterial | 12 | 2023 | 1048 | 1.910 |
Why?
|
| Syphilis | 4 | 2019 | 243 | 1.700 |
Why?
|
| Homosexuality, Male | 8 | 2023 | 1334 | 1.670 |
Why?
|
| Microbial Sensitivity Tests | 10 | 2023 | 1937 | 1.500 |
Why?
|
| Chlamydia Infections | 3 | 2021 | 365 | 1.480 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 2 | 2022 | 30 | 1.410 |
Why?
|
| Anti-Bacterial Agents | 15 | 2023 | 7407 | 1.370 |
Why?
|
| Pharynx | 3 | 2018 | 432 | 1.050 |
Why?
|
| Anal Canal | 2 | 2017 | 373 | 0.930 |
Why?
|
| Los Angeles | 7 | 2021 | 243 | 0.910 |
Why?
|
| HIV Infections | 10 | 2023 | 17352 | 0.900 |
Why?
|
| Sexual Partners | 4 | 2023 | 796 | 0.840 |
Why?
|
| Monkeypox virus | 1 | 2022 | 42 | 0.830 |
Why?
|
| Sexual Behavior | 6 | 2023 | 2180 | 0.830 |
Why?
|
| Syphilis Serodiagnosis | 2 | 2019 | 37 | 0.790 |
Why?
|
| Azithromycin | 2 | 2018 | 199 | 0.700 |
Why?
|
| Proctitis | 1 | 2019 | 41 | 0.650 |
Why?
|
| Mycoplasma genitalium | 1 | 2018 | 12 | 0.630 |
Why?
|
| Sex Offenses | 1 | 2023 | 352 | 0.620 |
Why?
|
| Asymptomatic Infections | 1 | 2019 | 131 | 0.610 |
Why?
|
| Mycoplasma Infections | 1 | 2018 | 120 | 0.610 |
Why?
|
| Medical History Taking | 1 | 2022 | 774 | 0.610 |
Why?
|
| Coxiella burnetii | 1 | 2018 | 37 | 0.600 |
Why?
|
| Prisoners | 1 | 2021 | 314 | 0.600 |
Why?
|
| Q Fever | 1 | 2018 | 38 | 0.600 |
Why?
|
| AIDS Serodiagnosis | 1 | 2019 | 220 | 0.580 |
Why?
|
| Meningitis, Bacterial | 1 | 2018 | 221 | 0.530 |
Why?
|
| Peru | 5 | 2023 | 891 | 0.520 |
Why?
|
| Epidemics | 1 | 2021 | 512 | 0.510 |
Why?
|
| Genotype | 6 | 2019 | 12990 | 0.500 |
Why?
|
| Immunoassay | 1 | 2018 | 745 | 0.480 |
Why?
|
| Ceftriaxone | 3 | 2022 | 175 | 0.460 |
Why?
|
| Endocarditis, Bacterial | 1 | 2018 | 436 | 0.460 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 2199 | 0.430 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 4352 | 0.390 |
Why?
|
| Cefixime | 2 | 2022 | 13 | 0.380 |
Why?
|
| California | 3 | 2021 | 1430 | 0.370 |
Why?
|
| Florida | 2 | 2022 | 431 | 0.360 |
Why?
|
| Seroepidemiologic Studies | 2 | 2021 | 397 | 0.340 |
Why?
|
| Humans | 45 | 2023 | 761572 | 0.330 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 1213 | 0.330 |
Why?
|
| Cities | 2 | 2022 | 546 | 0.330 |
Why?
|
| Poverty | 1 | 2021 | 2698 | 0.320 |
Why?
|
| Prevalence | 8 | 2021 | 15732 | 0.310 |
Why?
|
| Health Promotion | 1 | 2019 | 2214 | 0.290 |
Why?
|
| Pediatrics | 1 | 2022 | 3589 | 0.290 |
Why?
|
| Polymerase Chain Reaction | 3 | 2022 | 6075 | 0.280 |
Why?
|
| Unsafe Sex | 2 | 2019 | 238 | 0.270 |
Why?
|
| Chlamydia trachomatis | 2 | 2017 | 239 | 0.250 |
Why?
|
| Pandemics | 2 | 2021 | 8656 | 0.230 |
Why?
|
| Rectum | 2 | 2019 | 892 | 0.230 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2023 | 56 | 0.220 |
Why?
|
| Disease Outbreaks | 2 | 2023 | 1749 | 0.220 |
Why?
|
| Leukotriene E4 | 1 | 2023 | 75 | 0.210 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 3201 | 0.210 |
Why?
|
| Antibodies, Bacterial | 2 | 2018 | 1469 | 0.200 |
Why?
|
| Mass Screening | 4 | 2019 | 5428 | 0.200 |
Why?
|
| Adult | 13 | 2023 | 221203 | 0.160 |
Why?
|
| New York City | 1 | 2021 | 731 | 0.160 |
Why?
|
| Young Adult | 7 | 2023 | 59255 | 0.160 |
Why?
|
| Male | 16 | 2023 | 360842 | 0.160 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2019 | 209 | 0.160 |
Why?
|
| Hepatitis B, Chronic | 1 | 2023 | 410 | 0.150 |
Why?
|
| Female | 16 | 2023 | 392686 | 0.150 |
Why?
|
| Cytokines | 2 | 2023 | 7396 | 0.150 |
Why?
|
| Long-Term Care | 1 | 2022 | 633 | 0.150 |
Why?
|
| Saliva | 1 | 2022 | 828 | 0.150 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 588 | 0.150 |
Why?
|
| Hepatitis B | 1 | 2023 | 705 | 0.140 |
Why?
|
| Behavior Therapy | 1 | 2023 | 879 | 0.140 |
Why?
|
| Antigens, Viral | 1 | 2021 | 988 | 0.140 |
Why?
|
| Mentors | 1 | 2022 | 661 | 0.140 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2018 | 239 | 0.140 |
Why?
|
| Microbiological Techniques | 1 | 2017 | 97 | 0.140 |
Why?
|
| RNA, Bacterial | 1 | 2018 | 393 | 0.130 |
Why?
|
| Doxycycline | 1 | 2018 | 344 | 0.130 |
Why?
|
| Demography | 1 | 2021 | 1648 | 0.130 |
Why?
|
| Cephalosporins | 1 | 2017 | 198 | 0.130 |
Why?
|
| Macrolides | 1 | 2017 | 205 | 0.130 |
Why?
|
| Codon | 1 | 2017 | 601 | 0.120 |
Why?
|
| Fluoroquinolones | 1 | 2017 | 307 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2023 | 3162 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 14666 | 0.120 |
Why?
|
| Cervix Uteri | 1 | 2018 | 570 | 0.120 |
Why?
|
| Employment | 1 | 2021 | 1118 | 0.120 |
Why?
|
| Hydroxychloroquine | 1 | 2018 | 426 | 0.120 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 1039 | 0.120 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 26127 | 0.110 |
Why?
|
| Transsexualism | 1 | 2017 | 208 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 1899 | 0.110 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 329 | 0.110 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 1479 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 1526 | 0.110 |
Why?
|
| Social Stigma | 1 | 2019 | 769 | 0.110 |
Why?
|
| Medical Records | 1 | 2018 | 1408 | 0.100 |
Why?
|
| Adolescent | 5 | 2021 | 88324 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2021 | 41493 | 0.100 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 1668 | 0.100 |
Why?
|
| HIV Antibodies | 1 | 2018 | 1303 | 0.100 |
Why?
|
| Incidence | 2 | 2021 | 21355 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2023 | 80646 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2019 | 1394 | 0.090 |
Why?
|
| Drug Utilization | 1 | 2017 | 1188 | 0.090 |
Why?
|
| Thoracic Vertebrae | 1 | 2015 | 597 | 0.090 |
Why?
|
| HIV | 1 | 2017 | 1582 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 6312 | 0.080 |
Why?
|
| Insurance Coverage | 1 | 2021 | 1940 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 983 | 0.080 |
Why?
|
| Vaccination | 1 | 2021 | 3384 | 0.080 |
Why?
|
| Curriculum | 1 | 2022 | 3743 | 0.080 |
Why?
|
| Scoliosis | 1 | 2015 | 741 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2021 | 2498 | 0.080 |
Why?
|
| Public Health | 1 | 2021 | 2669 | 0.070 |
Why?
|
| United States | 3 | 2021 | 72335 | 0.070 |
Why?
|
| Mutation | 4 | 2023 | 30054 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 4544 | 0.070 |
Why?
|
| Internet | 1 | 2018 | 3093 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 3847 | 0.060 |
Why?
|
| Age Factors | 1 | 2021 | 18398 | 0.060 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 4527 | 0.060 |
Why?
|
| Child | 2 | 2022 | 80156 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2023 | 26198 | 0.050 |
Why?
|
| Risk Factors | 2 | 2021 | 74213 | 0.050 |
Why?
|
| Sierra Leone | 1 | 2023 | 169 | 0.050 |
Why?
|
| Genitalia | 1 | 2023 | 113 | 0.050 |
Why?
|
| Middle Aged | 5 | 2021 | 220920 | 0.050 |
Why?
|
| Hospitals, Public | 1 | 2023 | 202 | 0.050 |
Why?
|
| Genomics | 1 | 2017 | 5821 | 0.050 |
Why?
|
| Serine-Type D-Ala-D-Ala Carboxypeptidase | 1 | 2019 | 16 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 528 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2017 | 469 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2017 | 54426 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 1935 | 0.030 |
Why?
|
| Rural Population | 1 | 2023 | 2285 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 1302 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 169310 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 7581 | 0.010 |
Why?
|